ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Xinbao Pill in Chronic Heart Failure

Wang, Yuanping; Liu, Yuntao; Liu, Zhongqiu; Cheng, Yuanyuan*; Wang, Dawei*广东省人民医院; 广州中医药大学
Frontiers in Pharmacology2022-3-2DOI: 10.3389/fphar.2022.846867
4被引11阅读
引用收藏
分享

摘要

Objective: This study aimed to clarify the efficacy and safety of Xinbao pill (XBP) as an adjunctive treatment for chronic heart failure (CHF).Methods: Randomized controlled trials (RCTs) on the efficacy and safety of XBP in the treatment of CHF were searched from the six databases. The risk of bias assessment tool recommended by Cochrane Handbook 5.1 were used to assess the methodological quality of the included studies. RevMan 5.3 software was used for meta-analysis. The subgroup and sensitivity analyses were also performed. The grading recommendations assessment, development, and evaluation (GRADE) technique were used to assess the evidence's certainty.Results: Nine RCTs with a total of 882 patients were identified in this study. The meta-analysis demonstrated that XBP as adjunctive therapy was superior to conventional medicine alone for the treatment of CHF in improving the left ventricular ejection fraction (LVEF; MD = 5.34; 95% CI 4.68 to 5.99; p < 0.001), the total effective rate (RR = 1.21; 95% CI, 1.14 to 1.29; p < 0.001), the cardiac output (MD = 0.56; 95% CI 0.42 to 0.70; p < 0.001), the stroke volume (MD = 3.42; 95% CI 2.03 to 4.81; p < 0.001) and the 6-min walking distance (6-MWD; MD = 31.95; 95% CI 21.83 to 42.06; p < 0.001), meanwhile reducing the left ventricular end-diastolic diameter (LVEDD; MD = -3.22; 95% CI -4.03 to -2.42; p < 0.001) and left ventricular end-systolic dimension (LVESD; MD = -2.93; 95% CI -3.80 to -2.06; p < 0.001). Regarding safety, a total of 2.4% (11/456) adverse reactions occurred in the XBP groups while 3.9% (18/456) in the control group. The outcomes' evidentiary quality ranged from "very low" to "moderate".Conclusion: This study indicated that XBP as adjunctive therapy combined with conventional medicine seemed to be safe and more effective than conventional medicine alone in treating CHF. However, due to the poor methodological quality of the included RCTs, further well-designed RCTs are required to confirm the efficacy and safety of XBP.

学科与关键词

关键词
chronic heart failureXinbao pillmeta-analysissystematic reviewtraditional Chinese medicine (2592)
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-03-02
卷期
第 13 卷
页码
846867
DOI
10.3389/fphar.2022.846867
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Key-Area Research and Development Program of Guangdong Province [2020B1111100004]; National Natural Science Foundation of China [82174156]

作者

  • W

    Wang, Yuanping (第一作者)

    guangzhou univ chinese med

  • L

    Liu, Yuntao

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 5 位作者收起作者
  • L

    Liu, Zhongqiu

    guangzhou univ chinese med

  • C

    Cheng, Yuanyuan (通讯)

    guangzhou univ chinese med

  • W

    Wang, Dawei (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417